DrStockPick.com Stock Report!

Friday July 31, 2009

**************************************************************

Kaydon Corporation (NYSE:KDN) today announced that its Board of Directors declared a 5.9 percent increase in its regular quarterly dividend, to $.18 per share from $.17 per share. The dividend is payable on October 5, 2009 to shareholders of record as of the close of business on September 14, 2009. The indicated annual dividend rate will now be $.72 per share. This is the third consecutive year in which the Company has increased its quarterly dividend.

SPAR Group, Inc. (Nasdaq:SGRP) today reported financial results for the second quarter and six months ended June 30, 2009. Net revenues for the 2009 second quarter were $13.5 million, compared

...

Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of over 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-stage pivotal Phase 3 clinical trial results which are designed to support a filing for FDA approval.

Before reviewing the latest updates, below are two companies from the FDA Calendar with pending catalysts expected within the next week.

Savient Phama [SVNT: 12.06, -0.40 (-3.21%)] announced on 5/7/09 that its pending BLA for Krystexxa (pegloticase), a novel biological drug for

...

On March 2, 2009, Auxilium Pharmaceuticals (AUXL) submitted a biologic license application (BLA) to the U.S. FDA for Xiaflex seeking approval for the treatment of Dupuytren's contracture.The BLA filing represents a major milestone for the company and, if approved, would put the company squarely on the path to sustained profitability.On June 18, 2009, the U.S. FDA noted that its Division of Anesthesia, Analgesia and Rheumatology Products (DAARP) will hold an Arthritis Advisory Committee to discuss the pending application on September 16, 2009.Although this meeting has been scheduled for a month after the PDUFA action date of August 28, 2009, we are pleased to hear that hand and/or other orthopedic surgeons (potential users of the product) will be on the panel. We think that approval is likely after the panel meeting, probably in October or November 2009.The next potential ...